Search

Your search keyword '"Tommy Rampling"' showing total 2 results
Start Over Author "Tommy Rampling" Publisher massachusetts medical society
2 results on '"Tommy Rampling"'

1. Neonatal Monkeypox Virus Infection

Author

Padmanabhan Ramnarayan, Rebecca Mitting, Elizabeth Whittaker, Maria Marcolin, Ciara O’Regan, Ruchi Sinha, Aisleen Bennett, Moustafa Moustafa, Neil Tickner, Mark Gilchrist, Anthony Kershaw, and Tommy Rampling

Subjects
Infant, Newborn, Humans, Monkeypox, General Medicine, Monkeypox virus
Published
2022

2. A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA

Author

Katie Ewer, Tommy Rampling, Navin Venkatraman, Georgina Bowyer, Danny Wright, Teresa Lambe, Egeruan B. Imoukhuede, Ruth Payne, Sarah Katharina Fehling, Thomas Strecker, Nadine Biedenkopf, Verena Krähling, Claire M. Tully, Nick J. Edwards., Emma M. Bentley, Dhanraj Samuel, Geneviève Labbé, Jing Jin, Malick Gibani., Alice Minhinnic, Morven Wilkie, Ian Poulton, Natalie Lella, Rachel Roberts, Felicity Hartnell, Carly Bliss, Kailan Sierra-Davidson, Jonathan Powlson, Eleanor Berrie, Richard Tedder, B. Chir., Francois Roman, Iris De Ryck, Alfredo Nicosia, Nancy J. Sullivan, Daphne A. Stanley, Olivier T. Mbaya, Julie E. Ledgerwood, Richard M. Schwartz, Loredana Siani, Stefano Colloca, Antonella Folgori, Stefania Di Marco, Riccardo Cortese, Edward Wright, Stephan Becker, Barney S. Graham, Richard A. Koup, Myron M. Levine, Ariane Volkmann, Paul Chaplin, Andrew J. Pollard, Simon J. Draper, D. Phil., W. Ripley Ballou, Alison Lawrie, Sarah C. Gilbert, and Adrian V. S. Hill, Ewer, Katie, Rampling, Tommy, Venkatraman, Navin, Bowyer, Georgina, Wright, Danny, Lambe, Teresa, Imoukhuede, Egeruan B., Payne, Ruth, Katharina Fehling, Sarah, Strecker, Thoma, Biedenkopf, Nadine, Krähling, Verena, Tully, Claire M., J. Edwards., Nick, Bentley, Emma M., Samuel, Dhanraj, Labbé, Geneviève, Jin, Jing, Gibani., Malick, Minhinnic, Alice, Wilkie, Morven, Poulton, Ian, Lella, Natalie, Roberts, Rachel, Hartnell, Felicity, Bliss, Carly, Sierra-Davidson, Kailan, Powlson, Jonathan, Berrie, Eleanor, Tedder, Richard, Chir., B., Roman, Francoi, De Ryck, Iri, Nicosia, Alfredo, Sullivan, Nancy J., Stanley, Daphne A., Mbaya, Olivier T., Ledgerwood, Julie E., Schwartz, Richard M., Siani, Loredana, Colloca, Stefano, Folgori, Antonella, Di Marco, Stefania, Cortese, Riccardo, Wright, Edward, Becker, Stephan, Graham, Barney S., Koup, Richard A., Levine, Myron M., Volkmann, Ariane, Chaplin, Paul, Pollard, Andrew J., Draper, Simon J., Phil., D., Ripley Ballou, W., Lawrie, Alison, Gilbert, Sarah C., and Hill, and Adrian V. S.

Subjects
0301 basic medicine, Zaire ebolavirus, Male, T-Lymphocytes, viruses, medicine.disease_cause, Antibodies, Viral, chemistry.chemical_compound, 0302 clinical medicine, INFECTION, Vaccinia, 030212 general & internal medicine, 11 Medical and Health Sciences, B-Lymphocytes, Immunity, Cellular, PROTECTS NONHUMAN-PRIMATES, biology, ELISPOT, General Medicine, Middle Aged, Ebolavirus, 3. Good health, VIRUS, Cytokines, Female, Antibody, Life Sciences & Biomedicine, Adult, Pan troglodytes, Immunization, Secondary, IMMUNITY, Article, 03 medical and health sciences, Young Adult, Medicine, General & Internal, Immunity, General & Internal Medicine, medicine, Animals, Humans, Ebola Vaccines, QR355, Ebola virus, Science & Technology, Ebola vaccine, business.industry, Hemorrhagic Fever, Ebola, Virology, 030104 developmental biology, chemistry, Immunology, biology.protein, Adenoviruses, Simian, business, CHALLENGE
Abstract

BACKGROUND\ud The West African outbreak of Ebola virus disease that peaked in 2014 has caused more than 11,000 deaths. The development of an effective Ebola vaccine is a priority for control of a future outbreak.\ud \ud METHODS\ud In this phase 1 study, we administered a single dose of the chimpanzee adenovirus 3 (ChAd3) vaccine encoding the surface glycoprotein of Zaire ebolavirus (ZEBOV) to 60 healthy adult volunteers in Oxford, United Kingdom. The vaccine was administered in three dose levels — 1×1010 viral particles, 2.5×1010 viral particles, and 5×1010 viral particles — with 20 participants in each group. We then assessed the effect of adding a booster dose of a modified vaccinia Ankara (MVA) strain, encoding the same Ebola virus glycoprotein, in 30 of the 60 participants and evaluated a reduced prime–boost interval in another 16 participants. We also compared antibody responses to inactivated whole Ebola virus virions and neutralizing antibody activity with those observed in phase 1 studies of a recombinant vesicular stomatitis virus–based vaccine expressing a ZEBOV glycoprotein (rVSV-ZEBOV) to determine relative potency and assess durability.\ud \ud RESULTS\ud No safety concerns were identified at any of the dose levels studied. Four weeks after immunization with the ChAd3 vaccine, ZEBOV-specific antibody responses were similar to those induced by rVSV-ZEBOV vaccination, with a geometric mean titer of 752 and 921, respectively. ZEBOV neutralization activity was also similar with the two vaccines (geometric mean titer, 14.9 and 22.2, respectively). Boosting with the MVA vector increased virus-specific antibodies by a factor of 12 (geometric mean titer, 9007) and increased glycoprotein-specific CD8+ T cells by a factor of 5. Significant increases in neutralizing antibodies were seen after boosting in all 30 participants (geometric mean titer, 139; P

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results